Artelo Biosciences (US:ARTL) — Company Overview, News & Financial Data
Artelo Biosciences develops novel therapeutics targeting the endocannabinoid system to address unmet medical needs in various areas.
Artelo Biosciences
Artelo Biosciences (NASDAQ:ARTL) is a biopharmaceutical company focused on developing and commercializing a diverse portfolio of novel therapeutics targeting the endocannabinoid system. The company's operations span across the research and development of innovative treatments designed to address significant unmet medical needs in areas such as cancer, pain, and inflammation. With projects ranging from preclinical to phase trial stages, Artelo is dedicated to pushing the boundaries of science to improve health outcomes. The objective of Artelo is to leverage its expertise in the endocannabinoid system to bring groundbreaking therapies to market, ultimately improving patient care and advancing the field of medicine.
Snapshot
Operations
Products and/or services of Artelo Biosciences
- Development of ART27.13, a potent anorectic agent and appetite stimulant for cancer anorexia.
- Phase 1b/2a clinical trial for ART27.13 in cancer patients to improve lean body mass.
- Research on ART26.12, a novel fatty acid binding protein inhibitor aimed at targeting conditions such as anxiety and inflammation.
- Investigation into the potential therapeutic benefits of ART12.11, targeting cannabidiol for the treatment of psychological and pain disorders.
- Expansion into the study of cannabinoids and their role in cancer support care, focusing on pain management and appetite stimulation.
- Exploration of non-cannabinoid pathways for the development of novel therapeutics in major unmet medical needs.
Artelo Biosciences executive team
- Mr. Gregory D. Gorgas M.B.A.President, CEO, Secretary & Director
- Mr. Mark E. Spring CPACFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
- Dr. Andrew Yates Ph.D.Senior VP & Chief Scientific Officer
- Dr. Steven D. Reich M.D.Chief Medical Officer
- Mr. Jason H. BaybuttSenior Vice President of Finance